Drug resistance is a growing concern with clinical use of tyrosine kinase inhibitors. Utilizing in vitro models of intrinsic drug resistance and stromal-mediated chemoresistance, as well as functional mouse models of progressive and residual disease, we attempted to develop a potential therapeutic approach designed to suppress leukemia recurrence following treatment with selective kinase inhibitors. The novel inhibitor of apoptosis (IAP), LCL161, was observed to potentiate the effects of tyrosine kinase inhibition against leukemic disease both in the absence and presence of a stromal protected environment. LCL161 enhanced the proapoptotic effects of nilotinib and PKC412, against leukemic disease in vitro and potentiated the activity of both kinase inhibitors against leukemic disease in vivo. In addition, LCL161 synergized in vivo with nilotinib to reduce leukemia burden significantly below the baseline level suppression exhibited by a moderate-to-high dose of nilotinib. Finally, LCL161 displayed antiproliferative effects against cells characterized by intrinsic resistance to tyrosine kinase inhibitors as a result of expression of point mutations in the protein targets of drug inhibition. These results support the idea of using IAP inhibitors in conjunction with targeted tyrosine kinase inhibition to override drug resistance and suppress or eradicate residual disease.
Introduction
The development of resistance in leukemia patients to treatment with targeted tyrosine kinase inhibitors is a growing area of concern. For instance, the Abelson (ABL) inhibitor imatinib 1, 2 has proven to be a highly effective, front line therapy for chronic myeloid leukemia (CML), a hematopoietic malignancy caused by the product of a reciprocal t(9;22) chromosomal translocation, BCR-ABL. 3 However, accelerated or blast crisis phase CML patients often relapse due to drug resistance resulting from the emergence of imatinib-resistant point mutations within the BCR-ABL tyrosine kinase domain 4 or amplification of the target gene. 5 As an approach to overriding imatinib resistance, we developed the second generation ABL inhibitor, nilotinib (AMN107, Tasigna), 6 which has been FDA approved for imatinib-resistant disease due to the development of BCR-ABL point mutations, as well as for newly diagnosed CML patients.
Approximately 30% of acute myeloid leukemia (AML) patients express a mutated form of the class III receptor tyrosine kinase, FLT3. 7 We developed the FLT3 inhibitor, PKC412, 8 which was administered in sequential and simultaneous combinations with daunorubicin and cytarabine induction and high-dose cytarabine consolidation and yielded clinical responses with transient and/or reversible side effects. 9 Generally, though, FLT3 inhibitors tested thus far clinically induce only partial and transient responses in patients when used as single agents. This suggests a need for development of novel agents that can either be used effectively alone or combined with other agents to suppress disease progression and prolong lifespan.
In addition to identifying and developing potent kinase inhibitors representative of novel and unique structural classes with the ability to override drug resistance due to changes in the target protein, there is a push towards gaining a better understanding of the mechanisms underlying drug resistance in CML and AML as they relate to the leukemic cell microenvironment. Clinical trial data with tyrosine kinase inhibitors show that while the peripheral blasts are rapidly depleted, residual disease is apparent in patient bone marrow. Stromal cells have been implicated, as they provide viability signals to leukemic cells that protect them from inhibitor effects. Indeed, the quantity of leukemic stem cells that rely on stroma to survive is predictive of disease outcome. 10 Thus, deregulated signaling molecules associated with viability/apoptotic signaling represent attractive targets for therapeutic intervention. Several strategies have emerged that may be effective in preventing drug resistance due to this, including the combination of targeted inhibitors with small molecule inhibitors of key components of major signaling pathways affecting the viability/expansion of leukemic cells. One potentially important therapeutic target is the viability signaling factor, second mitochondria-derived activator of caspase (Smac), which mediates apoptosis through the intrinsic pathway 11 and binds to and inhibits the inhibitor of apoptosis (IAP) family of proteins. 12, 13 Recent work has indicated that IAP inhibitors can target multiple IAPs (that is, XIAP, c-IAP) to enhance the activity of different pro-apoptotic signaling pathways.
14 However, the role of XIAP in intrinsic versus extrinsic death pathways is unclear; recent studies suggest that it has a more significant role in regulating death receptor-mediated apoptosis than intrinsic pathway-mediated cell death. 15 We have developed effective inhibitors of the IAP family of proteins, 12, 13 such as LBW242, 16 and its structural analog, LCL161, which bind to and inhibit multiple IAPs (that is, XIAP, c-IAP) to enhance the activity of different proapoptotic signaling pathways. LBW242 and LCL161 are of similar molecular weight and are related structurally. The C-terminal half of LCL161 differs from LBW242, but the N-terminal half is similar. LCL161 has been optimized for potency and pharmacokinetics, and is a candidate for clinical trial investigation for solid tumors.
We have previously demonstrated the ability of LBW242 to synergize with PKC412 in vivo against progressive mutant FLT3-positive leukemia. 16 Here, we show the ability of the LBW242 structural analog, LCL161, to kill both kinase inhibitor-sensitive and kinase inhibitor-resistant mutant FLT3-and BCR-ABL-positive cells. As observed with LBW242, LCL161 similarly synergizesFboth in vitro and in vivoFwith PKC412 against progressive mutant FLT3-positive leukemia. However, LCL161 also synergizes in vitro and in vivo with nilotinib against BCR-ABL-positive leukemia. In addition, the use of LCL161 in combination with nilotinib was demonstrated to significantly delay the onset of disease recurrence in an in vivo model of BCR-ABL-positive leukemia. These data underscore the potential clinical advantage to using a proapoptotic agent, such as an IAP inhibitor, in combination with kinase inhibition to potentially improve patient responsiveness to tyrosine kinase inhibitor treatment.
Materials and methods

Cell lines and cell culture
Ba/F3.p210 cells were obtained by transfecting the interleukin (IL)-3-dependent marine hematopoietic Ba/F3 cell line with a pGD vector containing p210BCR-ABL (B2A2) complementary DNA. [17] [18] [19] Murine hematopoietic 32D cells were transduced with retrovirus to express p210 BCR-ABL (32D.p210 cells). 20 Ba/F3 cells were stably transfected by electroporation with imatinib-resistant BCR-ABL constructs (pCI-neo Mammalian Expression Vector; Promega, Madison, WI, USA #E1841) harboring the point mutations T315I, F317L, F486S and M351T; transfectants were selected for neomycin resistance and IL-3-independent growth. 6 The IL-3-dependent murine hematopoietic cell line Ba/F3 was transduced with WT-FLT3-, FLT3-ITD-or FLT3-D835Y-containing murine stem cell retroviruses harboring a neomycin selectable marker, and selected for resistance to neomycin. 21, 22 Mutant FLT3-transduced cells were selected for growth in G418 (1 mg/ml).
PKC412-resistant Ba/F3 cell lines expressing FLT3 harboring mutations in the ATP-binding pocket (Ba/F3-N676D, Ba/F3-G697R) were previously developed. 23 The human AML-derived, FLT3-ITD-expressing cell line, MOLM-13 (DSMZ (German Resource Centre for Biological Material), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany), was engineered to express luciferase fused to neomycin phosphotransferase (pMMP-LucNeo) by transduction with a vesicular stomatitis virus glycoprotein-pseudotyped retrovirus as previously described. 24 All cell lines were cultured with 5% CO 2 at 37 1C in RPMI (Mediatech, Inc., Herndon, VA, USA) with 10% fetal calf serum and supplemented with 1% L-glutamine. Parental Ba/F3 cells were similarly cultured with 15% WEHI-conditioned medium as a source of IL-3. Transfected cell lines were cultured in media supplemented with 1 mg/ml G418.
Chemical compounds and biological reagents
Nilotinib, imatinib, PKC412 and LCL161 were synthesized by Novartis Pharma AG, Basel, Switzerland. Compounds were initially dissolved in dimethyl sulfoxide to make 10 mM stock solutions, and then were serially diluted to obtain final concentrations for in vitro experiments. Ara-c and doxorubicin were purchased from Sigma Chemical Co (St Louis, MO, USA).
Normal bone marrow colony assays
Human bone marrow cells were obtained from normal donors after obtaining informed consent on an institutional IRB approved protocol. Mononuclear cells were isolated from normal bone marrow by density gradient centrifugation through Ficoll-Plaque Plus (Amersham Pharmacia Biotech AB, Uppsala, Sweden) at 2000 r.p.m. for 30 min, followed by two washes in 1 Â phosphate-buffered saline. Normal human bone marrow was analyzed in a colony assay: plates of 5 Â 10 4 cells in 'complete' methylcellulose medium containing recombinant cytokines (contents: fetal bovine serum, rh SCF, rh granulocyte/ macrophage colony stimulating factor, rh IL-3, bovine serum albumin, methylcellulose in Iscove's MDM, 2-mercaptoethanol, rh erythropoietin, L-glutamine; MethoCult GFH4434, StemCell Technologies, Inc., Vancouver, BC, Canada) were prepared. The plates also contained LCL161 at the indicated concentrations. The plates were incubated at 37 1C in 5% CO 2 for 41 week, and then myeloid and erythroid colonies (early progenitors with erythroid and myeloid components: CFU-GM, CFU-E, BFU-E and CFU-GEMM) were counted on an inverted microscope.
Human bone marrow samples obtained from normal healthy donors were also investigated for responsiveness to LCL161 in liquid culture (Iscove's MDM, supplemented with 20% fetal calf serum, L-glutamine and a cytokine cocktail containing rh Flt-3 ligand (100 ng/ml), rh SCF (100 ng/ml), rh IL-3 (20 ng/ml), rh IL-6 (20 ng/ml) and rh granulocyte/macrophage colony stimulating factor (10 ng/ml)) in the presence of different concentrations of drug.
AML patient cells
Frozen vials of bone marrow from AML patients identified as harboring mutant FLT3 were thawed before processing using Human AML peripheral blood and bone marrow samples were investigated for responsiveness to LCL161 in liquid culture (Iscove's MDM, supplemented with 20% fetal calf serum and L-glutamine) in the presence of different concentrations of drug. Human AML samples were also analyzed via colony assay, as described above. AML patient characteristics are provided in Supplementary Table 1 .
Proliferation studies, apoptosis assays and cell cycle analysis
Cell counts for proliferation studies were obtained using the trypan blue exclusion assay, as previously described. 8 Error bars represent the s.e.m. for each data point. Programmed cell death of inhibitor-treated cells was determined using the Annexin-V-Fluos Staining Kit (Boehringer Mannheim, Indianapolis, IN, USA), as previously described. 8 Cell cycle analysis was performed as previously described. 8 
Drug combination studies
For drug combination studies, compounds were added simultaneously at fixed ratios to cells, and cell viability was determined Treating leukemia with Smac mimetics E Weisberg et al by trypan blue exclusion and expressed as the function of growth affected, drug-treated versus control cells. Synergy was assessed by Calcusyn software (Biosoft, Ferguson, MO, USA and Cambridge, UK), using the Chou-Talalay method. 25 The 
Bioluminescent mutant FLT3 model of AML
Ba/F3-FLT3-ITD cells were transduced with a vesicular stomatitis virus glycoprotein-pseudotyped retrovirus comprised of the firefly luciferase-coding region (from pGL3-basic; Promega) cloned into PMSCV puro (Clonetech, Mountain View, CA, USA). Cells were neomycin selected to produce the Ba/F3-FLT3-ITD (luc þ ) cell line.
Bioluminescence imaging was carried out as previously described. 6 Briefly, for administration to male NCR-nude mice (5-6 weeks of age; Taconic, Hudson, NY, USA), virus-and Mycoplasma-free cells were washed and resuspended in Hank's Balanced Salt Solution (Mediatech, Inc.) and administered via IV tail vein injection (800 000 cells/mouse). Anesthesized mice were imaged 1-3 days post-IV injection to generate a baseline used to establish treatment cohorts with matched tumor burden, and total body luminescence was measured as previously described. 24 Bioluminescent BCR-ABL model of CML 32D.p210 cells were transduced with a retrovirus encoding firefly luciferase (MSCV-Luc), and selected with G418 at a concentration of 1 mg/ml to produce the 32D.p210-luciferase (luc þ ) cell line. 32D.p210-luc þ cells free of Mycoplasma and viral contamination were washed once with Hank's Balanced Salt Solution (Mediatech, Inc.), and resuspended in Hank's Balanced Salt Solution before administration to mice.
Bioluminescence imaging was carried out as previously described. 6 Briefly, for administration to male or female NCRnude mice (5-6 weeks of age; Taconic), virus-and Mycoplasmafree cells were washed and resuspended in Hank's Balanced Salt Solution (Mediatech, Inc.) and administered via IV tail vein injection (650 000-1 000 000 cells/mouse). Anesthesized mice were imaged 1-2 days post-IV injection to generate a baseline used to establish treatment cohorts with matched tumor burden, and total body luminescence was measured as previously described. 24 
Drug formulations for in vivo studies
For the in vivo model of BCR-ABL-positive leukemia, solutions of nilotinib were prepared just before administration, by dissolving 100 mg in 1.0 ml of N-methylpyrrolidone to give a clear solution and diluting with 9.0 ml PEG300. For the in vivo model of mutant FLT3-positive leukemia, 6% w/w PKC412 in Gelucire 44/14 (Gattefosse, Saint-Priest, France) was diluted with 1 Â phosphate-buffered saline and warmed in a 42 1C water bath until liquid. The solution was then stored at 4 1C until used for gavage treatment of mice. For both CML and AML in vivo models, LCL161 was prepared by first wetting 10 mg powder stock with 30 ml water, and then dissolving in two equivalents (0.73 ml per mg of compound) of 6.0 N HCl. The resulting (clear) solution was brought up to 1 ml in pH 4.6 acetate buffer, and the resulting stock was stored frozen at À20 1C until used for gavage treatment of mice.
Results
Effects of IAP inhibitor treatment and FLT3 inhibition, alone and combined, on the growth, viability and cell cycle progression of mutant FLT3-expressing cells in vitro
We were interested in investigating the ability of LCL161 to inhibit the growth of mutant FLT3-expressing cells, both as a single agent, as well as combined with PKC412. LCL161 modestly inhibits the growth of FLT3-ITD-expressing cells when administered alone, with an IC50 ranging from B0.5 mM (Ba/F3-FLT3-ITD cells, data not shown) to B4 mM (MOLM13-luc þ cells (Figure 1 and Supplementary Figure 1) . The potency of LCL161 against the D835Y mutant was observed to be considerably higher, with an IC50 of B50 nM when tested against Ba/F3-D835Y cells (Supplementary Figure 2) . Treatment of MOLM13-luc þ cells with a combination of LCL161 and PKC412 led to significantly more killing of cells than either agent alone, with Calcusyn combination indices suggestive of synergy ( Figure 1a, Supplementary Figure 1 , Table 1 ).
PKC412 and LCL161 induced apoptosis of MOLM13-luc þ cells, as evidenced by an elevation in apoptotic fraction of drugtreated cells as compared with vehicle-control-treated cells (Figure 1b, Supplementary Figure 1) . The combination of PKC412 and LCL161 led to a higher induction of apoptosis than either agent alone (Figure 1b) .
We then investigated the effects of PKC412 and LCL161 on cell cycle progression of mutant FLT3-expressing cells. As shown in Figure 2 , PKC412 induced G1 arrest in mutant FLT3-expressing cells, similar to what has been previously observed. 8 In contrast, LCL161 had little effect on cell cycle progression as a single agent. G1 arrest was observed at highest concentrations of LCL161 and PKC412 combined (Figure 2 ).
The ability of LCL161 to override stromal-mediated rescue of mutant FLT3-expressing cells through positive combination with PKC412
Having established the ability of LCL161 to positively combine with targeted kinase inhibitors against mutant FLT3-positive leukemia, we were interested in exploring the potential of LCL161 to enhance the activity of targeted therapy in the context of residual disease resulting from a cytoprotective microenvironment. We first investigated whether or not stromalderived, secreted factor(s) could protect leukemia cells against the inhibitory effects of selective tyrosine kinase inhibition. We have previously demonstrated that partial stroma-mediated protection of BCR-ABL-positive leukemic cells from nilotinib treatment involved the cooperative interaction of members of a select panel of stromal-secreted viability factors, including IL-6 and granulocyte/macrophage colony stimulating factor. 26 Similar results were observed with mutant FLT3-positive leukemia cells treated with PKC412 in the presence of HS-5 stromalconditioned media (SCM) versus the same panel of stromalsecreted viability factors. 27 Here, we validated these earlier results in the context of stromal-mediated cytoprotection of PKC412 mutant FLT3-expressing cells. Stromal-mediated rescue of PKC412-treated, mutant FLT3-ITD-expressing cells was demonstrated using SCM derived from the HS-5 stromal cell line, as well as primary mouse stroma flushed from mouse femurs (Figures 3a and b) . SCM obtained from the flushed femurs of mice was also able to partially protect imatinib-treated 32D.p210-luc þ cells (Supplementary Figure 3) . These results support the notion that stromal-mediated protection of kinase inhibitor-treated leukemic cells appears to involve viability signals in the form of secreted growth factors.
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We investigated the ability of LCL161 to override stromalmediated chemoresistance by studying its effects on MOLM13-luc þ , cultured in the presence of SCM. Significantly, the combination of PKC412 and LCL161 leads to more killing of MOLM13-luc þ cells than either drug alone, both in the absence of SCM, as well as in its presence (Figures 3c and d,  Supplementary Figure 3C ). In the presence of SCM, LCL161 both enhanced the ability of PKC412 to inhibit proliferation of mutant FLT3-expressing cells (Figure 3c ), as well as the ability of PKC412 to promote apoptosis of these cells (Figure 3d ). It is important to note that while LCL161 enhances the ability of PKC412 to kill mutant FLT3-expressing cells in the presence of SCM, single agent LCL161-treated cells are protected by SCM to a similar extent as single agent PKC412-treated cells (Supplementary Figure 4) .
Effects of IAP inhibitor treatment and FLT3 inhibition, alone and combined, on the growth of mutant FLT3-expressing cells in vivo LCL161 significantly enhanced the ability of PKC412 to inhibit the growth of Ba/F3-FLT3-ITD-luc þ cells in vivo (vehicle versus PKC412 (P ¼ 0.047); vehicle versus PKC412 þ LCL161 (P ¼ 0.028); Figure 4 ). Differences between suppression of leukemia growth by PKC412 or LCL161 alone and the combination of PKC412 þ LCL161 were also significant Treating leukemia with Smac mimetics E Weisberg et al (PKC412 versus combination (P ¼ 0.024); LCL161 versus combination (P ¼ 0.032)), and percent spleen weights were smaller for PKC412 þ LCL161 treated mice than for mice treated with vehicle or either agent alone (Figure 4) .
In addition to PKC412, LCL161 was also shown to positively combine with the standard chemotherapeutic agents, Ara-c and doxorubicin, against FLT3-ITD-expressing cells (Supplementary Figure 5) and against D835Y-expressing cells (Supplementary Figure 6) . Combination indices generally suggested additive-tosynergistic effects for these combinations (Table 1 ). In contrast, the combination of LCL161 and PKC412 against D835Y-expressing cells was antagonistic (Table 1) . 
The clinical potential of LCL161 as a single agent was demonstrated by its ability to inhibit the growth of mutant FLT3-expressing cells derived from AML patients ( Table 2 and Supplementary Figure 7) . A normal bone marrow colony assay suggested a lack of drug effect at concentrations p2000 nM LCL161 (Supplementary Figure 7) . One AML patient, 'AML4,' responded to LCL161 at 100 nM with a loss of B80% viability (Supplementary Figure 7) .
Effects of IAP inhibitor treatment and ABL inhibition, alone and combined, on the growth of BCR-ABL-expressing cells in vitro and in vivo LCL161 inhibited the growth of Ba/F3.p210 cells with an IC50 of B100 nM (Figure 5a, Supplementary Figure 8) . As with mutant FLT3-expressing cells, LCL161 induces apoptosis of BCR-ABLexpressing cells in a concentration-dependent manner, with no significant effect on cell cycle progression (Supplementary Figure 8) . The combination of LCL161 and the ABL inhibitor, imatinib, was observed to be synergistic against BCR-ABLexpressing cells (Figure 5a , Table 1 ). An in vivo study demonstrated a positive combination effect of 16-days of treatment with low-moderate dose (20 mg/kg) nilotinib and LCL161 against BCR-ABL-expressing cells (Figures 5b and c) . Nilotinib and LCL161 both suppressed leukemia growth, and there was an additive effect achieved by combining both drugs, which was most apparent at the day 17 imaging point (P ¼ 0.0002). After treatments were stopped on day 17, there was rapid 'catch-up growth' in the treated groups, and as such there was only marginal prolongation of survival comparing combo treated to single treatment groups. Survival was significantly prolonged in the drug-treated groups compared with the vehicle group (Po0.0001; Figure 5d ).
Enhancement of in vivo effects of high-moderate doses of nilotinib by LCL161 on leukemia burden in mice
We were interested in expanding on the in vitro and in vivo data thus far generated to establish a therapeutic approach designed Treating leukemia with Smac mimetics E Weisberg et al to suppress leukemia recurrence following treatment with selective kinase inhibitors. Specifically, we attempted to develop murine cell line-based models allowing noninvasive quantitative bioluminescent imaging as a measure of drug effects on both progressive and residual disease burden. For this purpose, we focused efforts on BCR-ABL-positive leukemia as our disease model, as tyrosine kinase inhibitors, such as imatinib, nilotinib and dasatinib, are FDA-approved and in widespread clinical use for the treatment of CML. The determined ideal doses of nilotinib in these studies were sufficient to substantially reduce leukemia burden to visually undetectable levels, or levels comparable to starting, baseline, measurements. The effects of nilotinib were then tested in combination with LCL161, as a survival pathway blocking inhibitor, to determine whether levels of baseline or 'residual' leukemic disease could be suppressed further than what was achievable by nilotinib alone. Generally, the time of onset of disease recurrence following varying lengths of treatment with moderate-to-high dose nilotinib was compared between mice treated with nilotinib alone, mice treated with IAP inhibitor alone and mice treated with a combination of the two agents. An in vivo study was carried out that demonstrated a positive combination effect of 4-day, high dose (100 mg/kg) nilotinib and LCL161 (40-100 mg/kg) treatment against BCR-ABL-expressing cells. LCL161 showed transient activity as a single agent (Figure 6a, Supplementary Figure 9) , and the addition of LCL161 to nilotinib delayed tumor regrowth by a short duration (Figure 6b, Supplementary Figure 9) . In this study, high dose nilotinib treatment alone reduced leukemia burden initially to visually undetectable levels. This was followed by a steady rise in leukemia burden observed post-treatment, with nilotinib þ LCL161 treatment groups showing significantly lower tumor burden as compared with nilotinib alone (Supplementary Figure 9) .
In another in vivo study, a positive combination effect was demonstrated over 3 weeks of treatment with moderate-to-high dose (75 mg/kg) nilotinib and LCL161 (100 mg/kg) against BCR-ABL-expressing cells. Nilotinib alone initially suppressed leukemia growth, however, whereas disease recurrence was observed with nilotinib as a single agent, leukemia levels continued to remain inhibited by nilotinib combined with LCL161 ( Figure 6c ).
Inhibition of proliferation of drug-resistant cell lines by LCL161
In addition to the ability of LCL161 to enhance the activity of targeted kinase inhibitor therapies, both in the absence and the presence of a stromal-protected microenvironment, LCL161 also has demonstrated activity against drug-resistant cells expressing point mutations in the target proteins. LCL161 at 1000 nM was able to mostly or completely kill Ba/F3-derived cell lines conferring resistance to PKC412, which express FLT3-ITD harboring point mutations in the ATP-binding pocket of FLT3 23 ( Figure 7 ). LCL161 also showed activity at concentrations ranging from 100 to 1000 nM against Ba/F3 cells expressing various imatinib-and nilotinib-resistant BCR-ABL point mutations ( Figure 7) . Treating leukemia with Smac mimetics E Weisberg et al imatinib. In similar fashion, clinical studies of advanced AML patients treated with FLT3 kinase inhibitors revealed a delayed or marginal decrease in levels of bone marrow blasts, in contrast to a sizable decrease in levels of blasts in patient peripheral blood. In fact, FLT3 inhibition in a defined 'niche-like' in vitro environment was actually found to enhance, as opposed to inhibit, survival of CD34 þ CD38ÀCD123 þ leukemic stem and progenitor cells. 28 Taken together, these results suggest that this area of investigation is important for a better understanding of drug resistance mechanisms.
Highest tumor burden and residual disease were previously revealed in vivo in stroma-associated tissues in imatinib/ nilotinib-treated mice, suggesting that significant reservoirs for tumor growth appear to be tissues that are able to support normal hematopoietic and malignant stem cell development. 26 These studies, which showed a pattern of leukemia distribution consistent with what is observed in imatinib-and nilotinibtreated CML patients, were followed by a more in-depth analysis of stroma-leukemia cell interactions that lead to protection of leukemia cells from nilotinib-induced cytotoxicity. Partial stromal-mediated protection of BCR-ABL-positive leukemic cells from nilotinib treatment was found to involve the cooperative interaction of members of a select panel of stromal-secreted viability factors, including IL-6 and granulocyte/macrophage colony stimulating factor. 26 Similar results were observed with mutant FLT3-positive leukemia cells treated with PKC412 in the presence of HS-5 SCM versus the same panel of stromal-secreted viability factors. 27 We set out here to investigate whether pharmacological targeting of resistance mechanisms might synergize with existing, targeted therapies as a way to eventually improve patient outcomes by ablating, or delaying the onset of, residual disease. In our studies, we tested the combination of targeted therapies for CML and mutant FLT3 þ AML, with a novel agent, LCL161, which inhibits signaling pathways critical for survival of leukemic cells. We confirmed the cytoprotective effects of stroma on kinase inhibitor-treated leukemia cells, and we utilized this assay system to explore and demonstrate the ability of the novel IAP inhibitor, LCL161, to enhance the efficacy of targeted therapies to override stromal-mediated chemoresistance.
We also developed an in vivo assay system that allows monitoring of the growth of progressive disease, as well as baseline level or 'residual' disease resulting from treatment with a moderateto-high dose of kinase inhibitor. Importantly, we demonstrated the ability of LCL161 to delay the onset of recurring BCR-ABL-positive disease in mice carrying an extremely low tumor burden following treatment with moderate-to-high dose nilotinib.
The development of functional models of progressive and residual leukemic disease enable the potential identification and Treating leukemia with Smac mimetics E Weisberg et al
